[Analgesic efficacy of Famalgin and Imigran in patients with acute migraine attacks].
Migraine is a syndrome clinically manifested in attacks which dominant symptom is unilateral, rarely generalized, recurrent headache that can last for hours, and occasionally, days. According to different sources, it is considered that about 10-15% of world population suffers from some type of this syndrome. Migraine is most frequently clinically revealed in the age of 30-40, therefore in the most productive period with significant share in treatment costs and a great influence to the working ability of those patients. The aim of this trial was to determine analgesic efficacy of Imigran (sumatriptan) and Famalgin in the treatment of acute attacks of migraine headache. Trial results revealed significant analgesic efficacy of both preparations without significant differences in analgesic effect, with significantly better tolerability of Famalgin. It was concluded that both preparations were efficacious drugs for the treatment of headache as the most prominent clinical symptom of migraine, with significantly rarer and less pronounced adverse effects of Famalgin.
Jovicić
A
A
Raicević
R
R
Bosković
B
B
D000208:Acute Disease; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy*; D010147:Pain Measurement; D012702:Serotonin Antagonists / Q000627:therapeutic use; D018170:Sumatriptan / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D012702:Serotonin Antagonists; C041599:aspirin, metoclopramide drug combination; D018170:Sumatriptan; D008787:Metoclopramide; D001241:Aspirin